Breaking News, Collaborations & Alliances

Isis, Janssen in Autoimmune R&D Alliance

To develop antisense drugs to treat gastrointestinal autoimmune disorders

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals has entered into a global collaboration with Janssen Biotech to discover and develop antisense drugs to treat gastrointestinal autoimmune disorders. The collaboration combines Isis’ RNA-targeted technology platform and Janssen’s expertise in autoimmune disorders and therapeutic formulation to develop antisense drugs that can be locally administered, including oral delivery.   The agreement covers three programs. Isis will receive $35 million in upfront payments and is ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters